Category: Press Releases

NEW YORK, Feb. 4, 2023 /PRNewswire/ — Egret Therapeutics, a clinical-stage biotechnology company focused on developing transformative therapies for neurological conditions, today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for EGT 101 that is being studied for the treatment of Delayed Cerebral Ischemia (DCI) following aneurysmal subarachnoid… Continue reading Egret Therapeutics Receives FDA Clearance of IND Application for EGT 101 for Treatment of Delayed Cerebral Ischemia

NEW YORK, Jan. 3, 2023 /PRNewswire/ — Egret Therapeutics, a clinical-stage company focused on the treatment of neurological diseases, today announced the expansion of its Scientific Advisory Board (SAB) with the appointment of three new members:   E. Sander Connolly Jr., M.D., serves as the Byron Stookey Professor and Chair of the Department of Neurological Surgery at the Vagelos College… Continue reading Egret Therapeutics Announces the Addition of Three New Members to its Scientific Advisory Board

NEW YORK, Feb. 15, 2022 /PRNewswire/ — Egret Therapeutics, a clinical-stage biotherapeutics company focused on the treatment of neurological diseases, announced today the completion of its pre-A financing. The funding was led by FAScinate Therapeutics, Inc, a clinical neurological diseases company, with participation from Turret Capital Management and private investors. The investment will be used to support the… Continue reading Egret Therapeutics completes oversubscribed pre-A financing round